GlassScriptPhysician profile
Irina A Urusova
NPI 1679581565
$6,583.89
in general payments reported to CMS, 2019-2025
20 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $794 · 2021: $1,532 · 2022: $922 · 2023: $762 · 2024: $685 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.87 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,636.68 | 2019-2025 | Ozempic, Rybelsus |
| Zealand Pharma US, INC. | $851.22 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $622.02 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $527.39 | 2019-2023 | |
| Lilly USA, LLC | $502.57 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.71 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $491.44 | 2019-2022 | |
| Mannkind Corporation | $367.60 | 2023-2025 | Afrezza |
| Merck Sharp & Dohme LLC | $306.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $152.19 | 2019 | |
| Valeritas, INC. | $118.97 | 2019 | |
| Corcept Therapeutics | $117.66 | 2024-2025 | Korlym |
| Amgen INC. | $114.01 | 2019 | |
| Dexcom, INC. | $107.33 | 2023-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $60.87 | 2025 | Tirosint, Flector, Licart |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $58.18 | 2022 | |
| Abbott Laboratories | $17.16 | 2019 | |
| Insulet Corporation | $15.21 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.50 | 2024 | NP Thyroid 60 |
| Abbvie INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Urusova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.